Intellia Therapeutics, Inc.
(NASDAQ:NTLA) stock is trading higher on Monday on additional positive findings from its global Phase 3 HAELO trial evaluating lonvo-z, its investigational CRISPR-based treatment for hereditary angioedema (HAE).
HAE is a rare genetic disorder that causes recurrent and unpredictable swelling attacks.
The company on Saturday presented the data during a late-breaking session at the European Academy of Allergy & Clinical Immunology Annual Congress 2026, while the results were also published in the New England Journal of Medicine.
Read Also: Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial Lonvo-Z Meets Key Secondary Endpoints In HAELO Study The latest data build on previously announced results showing that the study met its primary endpoint.
